Skip to main content
. 2020 Mar 24;16(3):e1008429. doi: 10.1371/journal.ppat.1008429

Fig 9. JQ-1 restricts viral infection in vivo.

Fig 9

(a) Experimental strategy for PRV-QXX challenge and JQ-1 treatment in mice. (b and c) IFN-β (b) and IL-1β (c) mRNA were assessed with RT-qPCR analysis in the lungs of mice (n = 4 per group). (d and e) IFN-β (d) and IL-1β (e) were quantified by ELISA in the serum in mice (n = 5 per group). (f) The survival rate was monitored daily for 10 days after PRV and PRV/JQ-1 challenge. (n = 12 per group). (g) The PRV genome was assessed with RT-qPCR analysis in the lungs of mice at 3 days post treatment of PRV and PRV/JQ-1 (n = 5 per group). (h) Experimental strategy for VSV-GFP challenge and JQ-1 treatment in mice. (i-k) The VSV genome was assessed with RT-qPCR analysis in the lung (i), spleen (j) and liver (k) of mice at 18 h post treatment of VSV and VSV/JQ-1 (n = 5 per group). (l) H&E stained images of lungs sections from mice treated as in g and i. Scale bar, 100 μM. All data are shown as mean ± SD based on three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 determined by two-tailed Student’s t-test.